
CGON Stock Forecast & Price Target
CGON Analyst Ratings
Bulls say
CG Oncology Inc. presents a promising outlook due to its advanced stage in clinical trials for cretostimogene grenadenorepvec, specifically addressing high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC). The potential for strong market positioning stems from the candidate's differentiated efficacy and durability, which are likely to enhance clinical adoption as it meets the significant unmet need for next-generation therapies that improve patient quality of life and resource efficiency. Additionally, the anticipated expansion into previously untreated populations, alongside projected peak revenues of approximately $1.0 billion for high-risk BCG-unresponsive NMIBC, underscores a substantial market opportunity supporting a positive long-term financial outlook for the company.
Bears say
The potential for CG Oncology's stock to perform poorly is primarily driven by several fundamental concerns regarding its lead product candidate, cretostimogene grenadenorepvec. A hazard ratio below 0.7 or a recurrence-free survival rate below 75% could significantly limit its market adoption, thereby undermining the company's expansion plans in treating intermediate-risk non-muscle invasive bladder cancer (NMIBC). Additionally, reliance on regulatory approvals presents a risk; any delays or negative trial outcomes could stifle commercialization efforts and diminish investor confidence.
This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
CGON Analyst Forecast & Price Prediction
Start investing in CGON
Order type
Buy in
Order amount
Est. shares
0 shares